Aromatic Amino Acid Decarboxylase Inhibitors

Compounds and drugs that block or inhibit the enzymatic action of AROMATIC AMINO ACID DECARBOXYLASES. Pharmaceutical agents in this category are used in conjunction with LEVODOPA in order to slow its metabolism.

Also Known As:

DOPA Decarboxylase Inhibitors; Dihydroxyphenylalanine Decarboxylase Inhibitors; Aromatic L Amino Acid Decarboxylase Inhibitors; Decarboxylase Inhibitors, Aromatic-L-Amino-Acid; Decarboxylase Inhibitors, DOPA; Decarboxylase Inhibitors, Dihydroxyphenylalanine; Inhibitors, Aromatic-L-Amino-Acid Decarboxylase; Inhibitors, DOPA Decarboxylase; Inhibitors, Dihydroxyphenylalanine Decarboxylase; Aromatic-L-Amino-Acid Decarboxylase Inhibitors

Networked: 16 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Therapeutic Uses: 47080
    - Central Nervous System Agents: 51
      - Anti-Dyskinesia Agents
        Antiparkinson Agents: 129
        Aromatic Amino Acid Decarboxylase Inhibitors: 16
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Aromatic Amino Acid Decarboxylase Inhibitors: 16

Experts

1.	Abril-Jaramillo, J: 1 article (12/2021)
2.	Almeida, F: 1 article (12/2021)
3.	Bermejo, P: 1 article (12/2021)
4.	Borrue, C: 1 article (12/2021)
5.	Caballol, N: 1 article (12/2021)
6.	Campins-Romeu, M: 1 article (12/2021)
7.	Clavero, P: 1 article (12/2021)
8.	García-Caldentey, J: 1 article (12/2021)
9.	Gómez-Mayordomo, V: 1 article (12/2021)
10.	Labandeira, C: 1 article (12/2021)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/2016 - "Aim of this review is to report on the most recent investigations regarding new DOPA decarboxylase inhibitors that could represent the starting point for possible Parkinson's disease drugs development. " 01/01/2016 - "Parkinson's Disease: Recent Updates in the Identification of Human Dopa Decarboxylase Inhibitors." 06/10/2010 - "However, neither in clinical use nor in experimental models of Parkinson's disease have the timing and dose of dopa decarboxylase inhibitors been thoroughly explored. " 09/01/1978 - "Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease." 05/23/2023 - "Levodopa (L-DOPA) treatment, combined with the administration of dopa-decarboxylase inhibitors (DDCIs), is still the most effective symptomatic treatment of Parkinson's disease (PD). "
2.	Parkinsonian Disorders (Parkinsonism) 07/01/1976 - "[Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine]."
3.	Disease Progression 07/01/1976 - "[Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine]."
4.	Myoclonus (Nocturnal Myoclonus) 07/01/1978 - "5-Hydroxytryptophan has been found to be beneficial when administered alone or in combination with extracerebral aromatic amino acid decarboxylase inhibitors for therapeutic purposes in various disorders in which myoclonus is prominent. "

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Droxidopa
3.	Sulfates (Sulfates, Inorganic)
4.	Homocysteine
5.	Cysteine (L-Cysteine)
6.	Transferases
7.	Dopamine (Intropin)
8.	opicapone
9.	entacapone (Comtan)
10.	catechol (pyrocatechol)

Related Therapies and Procedures

1.	Therapeutics